Robin Sherrington - Xenon Pharmaceuticals Sr. VP of Bus. and Corporate Devel.

XENE Stock  USD 40.47  0.28  0.70%   

SVP

Mr. Robin Sherrington, Ph.D. is a Executive Vice President Strategy Innovation of Xenon Pharmaceuticals Inc. since March 2019. Dr. Sherrington previously served as our Executive Vice President, Business Corporationrationrate Development since March 2018, as our Senior Vice President, Business Corporationrationrate Development since February 2012, as our Vice President, Business Corporationrationrate Development from January 2010 to February 2012, and has held various positions in business development and other departments since joining us in March 2001. Prior to joining us, Dr. Sherrington worked at Pfizer, Inc., a global pharmaceutical company, as a neuroscientist from 1999 to 2001 since 2019.
Age 64
Tenure 6 years
Professional MarksPh.D
Phone604 484 3300
Webhttps://www.xenon-pharma.com
Sherrington also previously served as Director of Neuroscience, from 1996 to 1999, at the biotechnology companies Axys Pharmaceuticals and Sequana Therapeutics. Prior to 1996 Dr. Sherrington was a postdoctoral fellow at University of Toronto and received his Ph.D. from the University College London, and his B.Sc. with honors from University of Reading.

Xenon Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.1892) % which means that it has lost $0.1892 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2671) %, meaning that it created substantial loss on money invested by shareholders. Xenon Pharmaceuticals' management efficiency ratios could be used to measure how well Xenon Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Xenon Pharmaceuticals currently holds 10.9 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Xenon Pharmaceuticals has a current ratio of 56.7, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Xenon Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. Xenon Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 149 people. Xenon Pharmaceuticals (XENE) is traded on NASDAQ Exchange in USA. It is located in 3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8 and employs 251 people. Xenon Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Management Performance

Xenon Pharmaceuticals Leadership Team

Elected by the shareholders, the Xenon Pharmaceuticals' board of directors comprises two types of representatives: Xenon Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xenon. The board's role is to monitor Xenon Pharmaceuticals' management team and ensure that shareholders' interests are well served. Xenon Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xenon Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
CMA CPA, CEO Pres
MBA MPH, Chief Officer
Sherry Aulin, Chief Officer
Christopher MD, Chief Officer
Andrea JD, Chief Secretary
Robin Sherrington, Sr. VP of Bus. and Corporate Devel.
MBA MSc, Ex Operations
Shelley BA, Executive Resources
James Empfield, Senior Vice President - Drug Discovery

Xenon Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xenon Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Xenon Pharmaceuticals is a strong investment it is important to analyze Xenon Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Xenon Pharmaceuticals' future performance. For an informed investment choice regarding Xenon Stock, refer to the following important reports:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.
For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenon Pharmaceuticals. If investors know Xenon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Xenon Pharmaceuticals is measured differently than its book value, which is the value of Xenon that is recorded on the company's balance sheet. Investors also form their own opinion of Xenon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Xenon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Xenon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.